stockrowInfuSystems Holdings, Inc.
INFU Healthcare Medical Devices
InfuSystems Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $143.4 million, up 6.36% from fiscal 2024.
- Revenue
- +2.59%
- EPS
- +33.3%
- Free cash flow
- −66.5%
- Total debt
- −22.5%
Quarter to June 2026, against a year earlier
Follow INFU
Alert me
InfuSystems Holdings, Inc. (INFU) EV/Sales
As of 5 November 2026, InfuSystems Holdings, Inc. (INFU) trades at a EV/Sales of 2.0×. Over the past ten years it has ranged from 0.9× (May 2017) to 4.9× (May 2021); the current reading is higher than 72% of that period. That is below the Medical Devices industry median of 2.7× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.4× | (6.60%) |
| FY2024 | 1.5× | (22.07%) |
| FY2023 | 1.9× | (0.11%) |
| FY2022 | 1.9× | (48.16%) |
| FY2021 | 3.7× | (10.58%) |
| FY2020 | 4.2× | 66.05% |
| FY2019 | 2.5× | 63.80% |
| FY2018 | 1.5× | 39.24% |
| FY2017 | 1.1× | (10.09%) |
| FY2016 | 1.2× | (12.15%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.5× | 3.75% |
| Mar 2026 | 1.4× | 1.90% |
| Dec 2025 | 1.4× | (14.28%) |
| Sep 2025 | 1.6× | 47.60% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LAB Standard BioTools Inc. compare | −2.5× |
| RXST RxSight, Inc. compare | −0.4× |
| TMCI Treace Medical Concepts, Inc. compare | 1.4× |
| INFU InfuSystems Holdings, Inc. | 2.0× |
| ELMD Electromed, Inc. compare | 2.7× |
| TLSI TriSalus Life Sciences, Inc. compare | 4.3× |
| CLPT ClearPoint Neuro, Inc. compare | 6.0× |
| PROF Profound Medical compare | 9.6× |
| QSI Quantum-Si Incorporated compare | 121× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)